Addex Therapeutics (NASDAQ:ADXN) Share Price Crosses Above 50-Day Moving Average – Should You Sell?

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) shares passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $3.20 and traded as high as $6.50. Addex Therapeutics shares last traded at $5.29, with a volume of 22,130,279 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Friday, October 2nd. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Addex Therapeutics Stock Performance

The company has a market capitalization of $6.51 million, a P/E ratio of -0.89 and a beta of 1.58. The firm’s fifty day moving average is $3.20 and its 200-day moving average is $5.59.

Addex Therapeutics (NASDAQ:ADXN) last released its quarterly earnings results on Friday, September 25th. The company reported ($1.48) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million for the quarter.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd. (NASDAQ: ADXN) is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company focuses on discovering and developing orally available small-molecule therapies that target G protein-coupled receptors (GPCRs), an important class of proteins involved in signaling throughout the nervous system. Addex’s approach centers on allosteric modulation, which aims to influence receptor activity at sites distinct from where natural signaling molecules bind.